Drug intelligence / Profile preview

PF-04171252

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-04171252 is a small molecule investigational drug developed by Pfizer. Detailed public information on PF-04171252 is minimal; however, it is referenced as the subject of a clinical pharmacology study evaluating the relationship between plasma drug levels and safety parameters following single oral dose administration of PF-05212365 (SAM-760) and PF-04171252 in healthy participants. Its exact mechanism of action, primary indication, and molecular details are not publicly available. Based on the context of the referenced studies, PF-04171252 may have been developed for central nervous system-related indications, though no definitive data are published confirming its targets, indication, or pharmacological class[3][5].

Brand names: PF-04171252PF04171252PF 04171252
Other names: PF-04171252PF04171252PF 04171252

Beyond the preview

Go deeper on PF-04171252.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-04171252.

Explore the full profile